Company Description
Encore Medical is a structural heart device company dedicated to the transcatheter closure of certain cardiac defects.We develop, manufacture, and market septal occlusion products, which are small, implantable devices delivered through a catheter inserted into a major blood vessel to permanently repair certain cardiac defects.
Our devices include patented technology that has been in use extensively outside of the U.S. Procedures are performed in a cardiac catheterization lab and reduce the need for open heart surgery or a lifetime of drug therapy, which are currently the primary alternative methods for treating these defects.
We have developed devices capable of providing effective, nonsurgical methods of correcting a variety of cardiac defects in both adults and children.
We have obtained CE Mark approval for our products, which is a prerequisite for the general sale of medical devices in the European Union and are currently marketing and selling our septal occlusion devices for the closure of certain cardiac defects through distribution partners in countries outside of the United States.
Country | United States |
Founded | 2017 |
Industry | Medical Devices |
Sector | Healthcare |
Employees | 16 |
CEO | Joseph A. Marino |
Contact Details
Address: 2975 Lone Oak Drive, Suite 140 Eagan, MN 55121 United States | |
Phone | (651) 797-0913 |
Website | encore-medical.com |
Stock Details
Ticker Symbol | EMI |
Exchange | NYSEAMERICAN |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001838003 |
Employer ID | 82-2906303 |
Key Executives
Name | Position |
---|---|
Joseph A. Marino | Chairman of the Board of Directors, President and Chief Executive Officer |
Peter M. Buonomo | Senior Vice President, Director |
Scott S. Robinson | Treasurer |
Timothy G. Laske, PhD | Director |
Christopher J. Turnbull | Director |
Todd C. Johnson | Director |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Sep 15, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
May 3, 2022 | D | Notice of Exempt Offering of Securities |
Dec 28, 2020 | D | Notice of Exempt Offering of Securities |